About Alcresta Therapeutics


Alcresta develops novel products that deliver enzymatic solutions to those living with rare diseases. Based in Massachusetts, Alcresta Therapeutics has achieved significant commercial milestones, created an extensive intellectual property portfolio, optimized production capabilities, and developed exciting scientific data supporting its products and technology platform.
 

Mission + Values

Enzyme products
designed for
enteral nutrition

Mission + Values

Alcresta Therapeutics is committed to delivering novel enzyme-based products that improve nutritional care for enterally fed patients living with rare diseases. Our values define our company and guide our business every day:

#

Innovation

We develop innovative medical devices that deliver enzymatic solutions

#

Leadership

We are paving a new therapeutic pathway in order to meet a critical unmet need

#

Passion

We care about making a difference in the lives of patients living with critical conditions and rare diseases

Alcresta Therapeutics Leadership

Daniel Orlando

Daniel Orlando

Chief Executive Officer

Daniel Orlando is the Chief Executive Officer of Alcresta Therapeutics.  He joins the team with more than 18 years of executive management and corporate development experience leading organizations through rapid growth in the development, manufacturing and commercialization of therapeutics and biologics.  Prior to joining Alcresta Therapeutics, Daniel was most recently the Chief Operating Officer of Vericel Corporation, an autologous cell therapy company, which purchased the cell therapy and regenerative medicine business unit from Sanofi Genzyme.  During his tenure, he led every function at Vericel, most recently, Sales, Marketing, Manufacturing, Engineering, and Research & Development.   Before joining Vericel, Daniel was one of Takeda North America’s early employee’s and held executive positions in Business Development, Marketing, and Sales as well as similar developmental roles at Abbott Laboratories.  Daniel holds a BA in Economics with Honors from the University of Florida and an MBA from Florida Atlantic University.

Bill Scheinler

Bill Scheinler

Chief Legal and Compliance Officer and Secretary

Bill Scheinler is Chief Legal and Compliance Officer and Secretary at Alcresta Therapeutics. He brings years of experience as a leader in public and private medical device and pharmaceutical companies, and as a specialist in compliance, contracting, mergers and acquisitions, and licensing. Bill was previously Vice President, Associate General Counsel for Ikaria, Inc., where he helped transform a business that was expected to face generic competition into a durable customer service-focused franchise with growing revenues, resulting in a five-fold increase in enterprise value. Among his responsibility at Ikaria were driving and supporting multiple in-licensing and product acquisition/divestiture transactions, the spin-out of the company’s R&D business to a stand-alone public company, developing effective and compliant business sustainability strategies, resolving complex, high value commercial disputes, and overseeing company contracting, including contracts with customers and key suppliers. Prior to joining Ikaria, Bill was Associate General Counsel at VIASYS Healthcare, Inc., a public healthcare technology company with four business units focused in respiratory care, neurology, medical disposables, surgical products, and orthopedics. At VIASYS, he supported the company’s global expansion strategy, including the acquisition of 11 companies to grow the company’s revenues by four times and enterprise value by more than three times. Before joining VIASYS, Bill was in the business and finance group at Morgan, Lewis & Bockius LLP, with a focus in technology transactions, licensing, outsourcing, supply and distribution arrangements, and mergers and acquisitions. Bill holds a J.D. from Temple University - James E. Beasley School of Law and an M.A. in International Policy Analysis from Middlebury Institute of International Studies at Monterey.

Eric R. First, M.D.

Eric R. First, M.D.

Chief Scientific Officer

Eric R. First, M.D., is Chief Scientific Officer at Alcresta Therapeutics. He has over 20 years of executive experience across the pharmaceutical, biotechnology, consumer health, medical device, and food & nutrition industries. Across these sectors, Dr. First has expertise in discovery research, translational medicine, medical and clinical research, innovation, product development, intellectual property, and business development. Prior to moving into the life sciences industry (drugs and devices), he held various management positions in the nutritional food services industry; managing and opening new dietary and nutrition departments for a number of hospitals and institutions. Prior to Alcresta Therapeutics, Dr. First was most recently the Chief Medical Officer and Head of Compliance at Sirtex Medical, Inc, a medical device oncology company, where he established the Medical Affairs Department in the Americas and headed up compliance activities for the Region. Prior to Sirtex Medical, he was the Vice President of Medical Affairs at Ipsen, Biopharmaceuticals, and was the Vice President of Global Innovation and Product Development at Bayer Healthcare’s Consumer Health Division. Prior to Bayer, Dr. First was a National Director of Medical Affairs at Allergan Inc. During his tenure at Allergan, he submitted over 150 records of invention; numerous of which are issued patents or in the publication phase. He was also instrumental in developing several indications and in conducting first in man use of toxin in non-muscle pain conditions (arthritis). His initial background into the field included basic science research on the therapeutic use of botulinum toxin in the Department of Neuropharmacology at Boston University School of Medicine and Clinical research was conducted at both Boston University and Harvard Medical School affiliated hospitals. As a result of his research investigating the use of botulinum toxin in pain and inflammatory conditions, he founded First BioTech, LLC, a specialty biotechnology company to further develop that technology which was subsequently licensed to Allergan. Dr. First received his medical degree from Boston University School of Medicine, and has an Associate Degree in Food and Nutrition Management from Southwestern Wisconsin Technical Institute.

Jason Weiner

Jason Weiner

Chief Commercial Officer

Jason Weiner is the Chief Commercial Officer of Alcresta Therapeutics. He joins the team with more than 17 years of industry and strategy consulting experience in the biopharmaceutical industry.  Prior to Alcresta, Jason was the Vice President of Marketing and Market Access at Vericel Corporation, an autologous cell therapy company, where during his tenure he led all marketing and market access related activities for the cell therapy and regenerative medicine franchise. Included was the expansion and build-out of the commercial team and development of an innovative patient access and distribution program. Jason held developmental Sales roles at Pfizer and Astellas before leading strategy engagements as a consultant at Charles River Associates where he advised on issues related to customer engagement, payer marketing, drug launches, physician research, sales force alignment, market access, and pricing strategy. Jason holds a BA in History from Union College and an MBA from Boston College.

Alcresta Therapeutics Board of Directors

Steve Dubin

Principal, SDA Ventures LLC

Steve Dubin is currently a principal at SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health, wellness and nutritional products markets. Mr. Dubin is also the former chief executive officer of Martek Biosciences Corporation, a leader in long-chain polyunsaturated (LCPUFA) nutritional products. Mr. Dubin played a key role in developing Martek’s business from an R&D company to a fully integrated, profitable, commercial organization with more than $470 million in annual sales. He served in a variety of positions during 14 years with the company before his election to chief executive officer in July 2006, and served in that capacity until the sale of the company to Royal DSM in 2011 for approximately $1.1 billion. Mr. Dubin holds a B.S. from the University of Maryland, College Park and a J.D. from the National Law Center at the George Washington University.

Todd Creech

Managing Partner, HealthQuest Capital

Todd Creech is currently a Partner at HealthQuest Capital. HealthQuest is a venture growth equity fund, investing in healthcare innovation across most of the healthcare spectrum: medical technologies, diagnostics, digital health, and innovative services. He currently also serves as board member of HealthQuest portfolio company BioIQ and an observer for HealthChannels, Springbuk, InMediata, and Venus Concept.

Prior to joining HealthQuest, he was CFO and Treasurer of ZS Pharma (IPO in 2014 and sold to AstraZeneca in 2015). Mr. Creech was the CFO and led business development activities for Sarcode which was sold to Shire in 2013.  He was also the CFO of Sirion Therapeutics, an ophthalmic company that was sold to Alcon and Bausch & Lomb in 2010. During his CFO tenure he has raised more than $500 million in equity and debt, helping to build operations and companies that generated over $3.5 billion in exits.

Earlier in his career, Mr. Creech did healthcare venture investing for Quintiles and worked with SRI International. He has also co-founded two companies; a spectroscopy platform spinout of Duke University (Centice) and a specialty pharmaceutical company (TLC Pharma).

Mr. Creech holds bachelor's degrees in Finance and Accounting from Miami (Ohio) University where he was also a scholarship baseball player, and an MBA from Duke University. He is an Executive-in-Residence and Committee Board Member for The H. Lee Moffitt Cancer Center. He is an advisor to Femasys, a privately held medtech company developing women’s health products. Further, Mr. Creech is also on the boards of Southeast Bio and the Southeast Medical Device Association.

Stephen Kraus

Partner, Bessemer Venture Partners

Stephen Kraus, a partner in the Cambridge, Mass. office, has worked with Bessemer Venture Partners since 2004 and focuses on the healthcare sector. Mr. Kraus has been actively involved in Bessemer’s investments in Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ: AFFY); Aveo (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec; Verastem (NASDAQ: VSTM); and Restore Medical (NASDAQ: REST, acquired by Medtronic). He currently sits on the boards of Verastem, Allena Pharmaceuticals, Alcresta, Liazon and OvaScience, and is actively involved in BVP’s investments in Acceleron and Proteon. Prior to joining Bessemer, Mr. Kraus was a director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and operations director for the Democratic nominee for governor of Massachusetts. Mr. Kraus graduated summa cum laude with a B.A. from Yale University and earned his M.B.A. from Harvard, where he was a Baker Scholar. He serves on the boards of the New England Venture Capital Association (NEVCA), the Achievement Network, and Interise.

Alexey Margolin, Ph.D.

Chairman of the Board, Allena Pharmaceuticals

Alexey Margolin, Ph.D., co-founded and, at one time, served as the CEO of Alcresta Therapeutics. Dr. Margolin also served as President and CEO of Allena Pharmacauticals which he also co-founded and where he currently serves as Chairman of the Board. Prior to Allena and Alcresta, Dr. Margolin co-founded Alnara Pharmaceuticals in 2008, where he was President and CEO until 2010 when the company was acquired by Eli Lilly. Previously Dr. Margolin also served as chief scientific officer of Altus Pharmaceuticals where he initiated and led several therapeutic programs based on protein crystallization technology. Dr. Margolin is an expert in the fields of protein drug development and enzymology. He is the author of more than 60 publications and is an inventor on several patents. In 2003, Dr. Margolin was elected fellow of the American Institute of Medicine and Biological Engineering. Dr. Margolin holds both his M.S. in chemistry and Ph.D. in bio-organic chemistry from Moscow University.

Alan Muney M.D.

Senior Healthcare Advisor, Pritzker Private Capital, Arsenal Capital, Bain Management Consulting, and NEA Venture Capital

Dr. Muney is currently a senior healthcare advisor for Pritzker Private Capital, Arsenal Capital, Bain Management Consulting, and NEA Venture capital.

Previously Dr. Muney served as Cigna’s Chief Medical Officer and Executive Vice President of Total Health and Network.  In his role as Chief Medical Officer, Dr. Muney was responsible for Cigna’s clinical strategy and policy, health advocacy programs, coverage policy, and quality measurement and improvement.  As lead for Total Health and Network, Dr. Muney was responsible for the market medical and clinical nurse executives, total health physician operations, total health clinical operations, and dental clinical operations, as well as medical, behavioral, and dental contracting.  Dr. Muney also oversaw Cigna’s team of doctors, dentists, nurses, and behavioral health clinicians involved in the company’s health management and wellness programs.

Before joining Cigna, Dr. Muney was an Executive Director in the Private Equity Group at The Blackstone Group, and the CEO of Equity Healthcare, which he founded to manage the healthcare costs of Blackstone’s portfolio companies.  While at Blackstone, he also served on the Board of Directors of Vanguard Health System and Team Health.  Prior to Blackstone, Alan was the Executive Vice President and Chief Medical Officer of Oxford Health Plans and Chief Medical Officer of United Healthcare of the Northeast region from 1998-2007.

Mr. Muney is board-certified in pediatrics, and received his B.S. in Biology and his Doctor of Medicine degrees from Brown University, and a Masters in Health Administration from the University of La Verne.

Daniel Orlando

Chief Executive Officer, Alcresta Therapeutics

Daniel Orlando is the Chief Executive Officer of Alcresta Therapeutics.  He joins the team with more than 18 years of executive management and corporate development experience leading organizations through rapid growth in the development, manufacturing and commercialization of therapeutics and biologics.  Prior to joining Alcresta Therapeutics, Daniel was most recently the Chief Operating Officer of Vericel Corporation, an autologous cell therapy company, which purchased the cell therapy and regenerative medicine business unit from Sanofi Genzyme.  During his tenure, he led every function at Vericel, most recently, Sales, Marketing, Manufacturing, Engineering, and Research & Development.   Before joining Vericel, Daniel was one of Takeda North America’s early employee’s and held executive positions in Business Development, Marketing, and Sales as well as similar developmental roles at Abbott Laboratories.  Daniel holds a BA in Economics with Honors from the University of Florida and an MBA from Florida Atlantic University.